ADCYAP1R1 and migraine disorder: While PACAP has been implicated in migraine, current efforts to antagonize PACAP-PAC1R signaling through the development of monoclonal antibodies to PACAP38 or PAC1R for treatment-resistant migraines [85,270,271,272] have not been successful.